Chest
-
OSA PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The most suitable treatment for OSAS is the CPAP. However there are patients who don't tolerate it. A therapeutic not surgical alternative is MAD . It consists of a plastic rod which being introduced in dental arcades produces the advance of the jaw and indirectly the advance of the tongue, hyoid and suprahyoidea musculature. All this implies a space and permeability increase of the top airway. Our objective is to evaluate the efficiency of the MAD, Herbst type, as a treatment for OSAS. This evaluation will be carried out by means of clinic and functional variables. ⋯ The following authors have nothing to disclose: Maria Pavón, Estefania Luque, Jose María Benitez, Jesús Sánchez, Andrés Vega Arias, Teodoro MontemayorNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Exacerbations are the most frequent cause of hospitalization and death among patients with COPD. Combinations of long-acting bronchodilators maximize bronchodilation and may reduce the risk of exacerbations. QVA149, a once-daily dual bronchodilator containing the long-acting β2-agonist (LABA) indacaterol and long-acting muscarinic antagonist (LAMA) glycopyrronium, improves lung function, breathlessness and rescue medication use compared with twice-daily salmeterol/fluticasone combination (SFC), in patients with moderate-to-severe COPD.1METHODS: In this 26-week, multicenter, double-blind study, patients ≥ 40 years with COPD (forced expiratory volume in 1 second [FEV1] ≥40% to <80% predicted and no history of exacerbations in the previous year) were randomized (1:1) to QVA149 110/50 µg or SFC 50/500 µg. In this post hoc analysis, we report the rate of mild, moderate or severe COPD exacerbations during 26 weeks of treatment with QVA149 or SFC. ⋯ Eric Bateman: Consultant fee, speaker bureau, advisory committee, etc.: Prof Eric Bateman has served on advisory boards for Boehringer Ingelheim, AstraZeneca, Elevation Pharma, Napp Pharma, Novartis, Almirall, Forest, and Merck and Takeda; has served as a consultant to Navigant Consulting, IMS consulting group, ALK-Abello, Almirall, Hoffman la Roche, and ICON; has been paid lecture fees by AstraZeneca, ALK-Abello, Chiesi, Boehringer Ingelheim, GlaxoSmithKline, Nycomed/Takeda, Novartis, Pfizer, and Indegene Lifesciences Ltd. Claus Vogelmeier: Consultant fee, speaker bureau, advisory committee, etc.: AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Janssen, Novartis, Pfizer, Almirall, Takeda, and Sterna Biologicals; has been paid lecture fees by AstraZeneca, Chiesi, GlaxoSmithKline, Janssen, Talecris, Novartis, Boehringer Ingelheim, Takeda, and Pfizer. Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Respiratory InfectionsSESSION TYPE: Slide PresentationsPRESENTED ON: Sunday, March 23, 2014 at 04:15 PM - 05:15 PMPURPOSE: The treatment of XDR-TB is less effective than that of other forms of TB because of the lack of efficacious anti-TB drugs so that the infection is frequently fatal. To investigate the efficacy and safety of linezolid containing chemotherapy in patients with XDR-TB in China. ⋯ The following authors have nothing to disclose: Shenjie Tang, Lan Yao, Xiaohui Hao, Xia Zhang, Gang Liu, Xin Liu, Meiying Wu, Linhai Zeng, Hua Sun, Yidian Liu, Jin Gu, Feishen Lin, Xiafang Wang, Zhanjun ZhangNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: The IGNITE program investigated the efficacy and safety of dual bronchodilation with once-daily QVA149 [fixed-dose combination of indacaterol (long-acting β2-agonist) and glycopyrronium (long-acting muscarinic antagonist)] for the treatment of patients with moderate-to-severe COPD. ⋯ Karen Mezzi: Employee: Novartis Employee Mark Fedele: Employee: Novartis Employee Hungta Chen: Employee: Novartis Employee Donald Banerji: Employee: Novartis EmployeeClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Asthma Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: We present a 52 year old patient masquerading as a "difficult to control asthmatic". Her ultimate diagnosis is common variable immunodeficiency complicated by recurrent pulmonary infections, follicular bronchitis, and organizing pneumonia. This diagnosis is rare, but should be entertained in our patient's age group. The common variable immunodeficiencies (CVID) are relatively frequently encountered syndromes of various types of B-cell activation or differentiation defects, most often diagnosed during late childhood or early adult life. (1-4) Clinical manifestations of CVID include recurrent infections of the respiratory tract and, less frequently, autoimmune, granulomatous, or lymphoproliferative disorders. ⋯ The following authors have nothing to disclose: Susan Mucha, Mark Lega, Marvin BalaanNo Product/Research Disclosure Information.